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Abstract: Granulomatosis with polyangiitis (GPA) is a systemic granulomatous inflammatory disease
characterized by small-to-medium vessel vasculitis due to Central Anti-Neutrophil Cytoplasmic
Antibody (C-ANCA). GPA commonly involves the lungs and the kidneys. Among the pulmonary
manifestations, diffuse alveolar hemorrhage (DHA) is a rare presentation of GPA that can present
with hemoptysis leading to acute onset of anemia and hemodynamic instability. An active
diagnostic workup including serologic titer of C-ANCA, imaging, intensive care, and aggressive
immunosuppression is the key to DAH management. We report a case of DAH secondary to GPA
that presented with hemoptysis leading to severe anemia, initially resuscitated symptomatically
and started on plasmapheresis with pulse steroids and cyclophosphamide. Timely diagnosis and
management led to a remarkable recovery of the pulmonary symptoms and imaging findings of DAH.
Keywords: diffuse alveolar hemorrhage; granulomatosis with polyangiitis; plasmapheresis;
prednisone; cyclophosphamide; rituximab
1. Introduction
Granulomatosis with polyangiitis (GPA) is a chronic granulomatous small-medium-vessel
necrotizing inflammation of the lungs and kidneys. It is one of the three antineutrophil cytoplasmic
antibody-associated vasculitides (AAV), the others being microscopic polyangiitis (MPA) and
eosinophilic granulomatosis with polyangiitis (EGPA) [1]. GPA is extremely rare in the United
States, with an incidence of only 8–10 cases per 1 million residents. The peak incidence of GPA is during
the sixth and seventh decades of life. It may involve any organ, including the lungs, kidney, heart,
skin, joints, and eyes [2]. The lung involvement can present as asymptomatic pulmonary nodules but,
in rare cases, can cause diffuse alveolar hemorrhage (DAH) that can present as massive hemoptysis
leading to hemodynamic decompensation. DAH can cause up to 60% mortality in GPA. The diagnosis
is challenging, given the nonuniform and nonspecific symptoms. DAH can be diagnosed with a
combination of pulmonary symptoms, positive serology, imaging, lung biopsy, and a flexible fiberoptic
bronchoscopy lavage with persistent bloody aliquots [3]. A flexible fiberoptic bronchoscopy is the
most definitive test for the diagnosis of DAH. Here, we present the case of a 60-year-old female with
DAH secondary to GPA that was treated with plasmapheresis, pulse steroids, and cyclophosphamide.
Medicina 2019, 55, 378; doi:10.3390/medicina55070378 www.mdpi.com/journal/medicina
Medicina 2019, 55, 378 2 of 9
2. Case Presentation
A 60-year-old female with a medical history of unexplained prolonged hematuria for the last four
years presented to the emergency department (ED) with complaints of hemoptysis, fever, myalgia,
and night sweats that had persisted for at least one week. She had no other comorbidities, and her
family history was unremarkable. Before coming to the ED, the patient experienced four episodes
of hemoptysis and was referred from urgent care to the ED due to the concern of acute anemia and
chronic kidney injury. The patient gave her informed consent for inclusion before participating in
the study.
On admission, vital signs included blood pressure of 162/93 mmHg, heart rate of 98 beats/minute,
respiratory rate of 24 breaths/minute, and oxygen saturation of 94%. A physical examination yielded
non-significant findings except for pallor, blood around the nares, and prominent right-sided pulmonary
crackles on auscultation.
The results of the initial laboratory tests, including hematology, metabolic panel, arterial blood
gas, and culture and sensitivity, are shown below in Table 1.
Table 1. Baseline laboratory values.
Analyte Baseline Reference Range
Hematology
WBC 21.8 K/mcL 4.5–11.0 K/mcL
Hemoglobin 5.8 gm/dL 12.0–16.0 gm/dL
RBC 2.10 M/mcL 4.00–5.20 M/mcL
Platelet count 356 K/uL 550 K/uL
Neutrophils 90.5% 43.0–77.0%
Lymphocytes 3.8% 13.0–44.0%
Monocyte 6.2% 2.0–14.0%
Eosinophil 0.1% 0.0–6.0%
Basophil 0.5% 0.0–2.0%
MCV 90.1 fl 80.0–100.0 fl
MCH 27.8 pg 27.0–34.0 pg
MCHC 30.8 gm/dL 32.0–36.0 gm/dL
RDW 17.4% 10.3–14.5%
PT 13.0 seconds 10.0–13.0 seconds
aPTT 27.4 seconds 27.0–36.0 seconds
Metabolic panel
ALT 7 U/L 7–35 U/L
AST 11 U/L 10–35 U/L
Total Bilirubin 0.3 mg/dL 0.1–1.2 mg/dL
BNP 616 pg/mL 1–100 pg/mL
C-reactive protein 178.3 mg/L 0.0–1.0 mg/L
ESR 116 mm/hr 0–20 mm/hr
Creatinine 8.83 mg/dL 0.40–1.60 mg/dL
BUN 70 mg/dL 8–22 mg/dL
e-GFR 5 ml/min/1.73 m2 90–120 ml/min/1.73 m2
Phosphorus 7.4 mg/dL 2.5–4.9 mg/dL
Calcium 8.3 8.5–10.5 mg/dL
Sodium 136 mEq/L 136–146 mEq/L
Vitamin D 25- Hydroxy 22.6 ng/mL 30.0–100.0 ng/mL
PTH 160.5 pg/mL 10.0–65.0 pg/mL
Arterial Blood Gases
pH 7.46 7.320–7.420
pCO2 31.2 mmHg 38.0–50.0 mmHg
HCO3 23.6 mmol/L 22.0–28.0 mmol/L
Anion gap 17 mmol/L 2–11 mmol/L
Lactate 1.0 mmol/L 0.0–2.2 mmol/L
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Table 1. Cont.
Analyte Baseline Reference Range
Culture and sensitivity
Sputum AFB Negative in three samples Negative
Stool culture Negative Negative
Urine culture Negative Negative
Blood culture Negative Negative
Abbreviations: WBC: white blood cells; RBC, red blood cells; MCV, mean corpuscular volume; MCH, mean
corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red blood cell distribution
width; PT, prothrombin time; aPTT, activated partial thromboplastin time; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; BNP, brain natriuretic peptide; ESR, erythrocyte sedimentation rate; BUN, blood urea
nitrogen; e-GFR, estimated glomerular filtration rate; PTH, parathyroid hormone; pCO2, partial pressure of carbon
dioxide; HCO3, bicarbonate; AFB, acid-fast bacillus.
Urine analysis and baseline antibody panel for diagnostic workup are shown in Tables 2
and 3 respectively.
Table 2. Detailed urine analysis with reflex microscopy.
Analyte Results
Appearance Cloudy (Reference: clear)
Color Yellow (Reference: yellow)
Urine pH 6.0 (Reference: 5.0–7.5)
Specific gravity 1.016 (Reference: 1.005–1.030)
Bilirubin Negative (Reference: negative)
Ketones Negative (Reference: negative)
Glucose Negative (Reference: negative)
Blood Large (Reference: negative)
Protein 1000 mg/dL (Reference: negative mg/dL)
Urobilinogen 1.0 (Reference: 0.2–1.0)
Nitrite Negative (Reference: negative)
Leukocyte esterase Negative (Reference: negative)
White blood cells urine >50 HPF (Reference: 0–4 HPF)
Red blood cells urine <50 HPF (Reference: 0–3 HPF)
Urine bacteria Negative (Reference: negative)
Squamous epithelial cells 0–4 HPF (Reference: 0–4 HPF)
Casts None (Reference: no cast)
Table 3. Baseline autoimmune panel.
Analyte Result Reference
ANA antibody 1:160 1:180
ANA pattern Homogenous
Anti-GBM antibodies Negative (<0.2 U) Negative: <1.0 UPositive: >1.0 U
C-ANCA Positive (1:320 titer)
Proteinase-3 antibody Positive (>150.0 units)
Negative: <20 units
Diffusely positive: 21.0–30.0 units
Positive: >30 units
Myeloperoxidase antibody Negative (5.1 units)
Negative: <20 units
Diffusely positive: 21.0–30.0 units
Positive: >30.0 units
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Table 3. Cont.
Analyte Result Reference
Anti-U1RNP Antibody Negative (0.4 AI) Negative: <1.0 AIPositive: ≥1.0 AI
Anti SCL-70 Negative (<0.2 AI) Positive: ≥1.0 AI
ASO Negative
Anti-DsDNA Negative (<12 IU/mL) Positive: >75 IU/mL
Hepatitis C Antibody Non-reactive
Hepatitis B Antibody Non-reactive (<10 mIU/mL) Reactive: ≥10 mIU/mL
C3 113 mg/dL 81–157 mg/dL
C4 25 mg/dL 13–39 mg/dL
Rheumatoid factor 22 IU/mL 0–13 IU/mL
Anti-SS-A-AB(RO) Negative; <0.2 AI Negative: <1.0 AIPositive: >1.0 AI
Cyclic Citrullinated
C-Peptide Ab <8 U
Negative: ≤39 U
Positive: >40 U
Abbreviations: ANA, anti-nuclear antibodies; GBM, glomerular basement membrane; C-ANCA, cytoplasmic
anti-neutrophilic antibodies; U1RNP, U1-ribonucleoprotein; SCL-70, scleroderma-70; ASO, anti-streptolysin O;
DsDNA, double-stranded DNA; C3 and C4, complement components 3 and 4. Baseline chest radiography and
status post treatment are shown in part A and B of Figure 1, respectively.
A baseline chest radiography finding is shown in Figure 1. A high-resolution computed
tomography (HRCT) of the chest is shown below in Figure 2.
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Figure 3. (A) Bronchoscopy showing blood (blue arrow) in the right middle lobe in the 
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Figure 2. High-resolution computed to ography (HRCT) scan showing a nodular cavity with
infiltration in the right upper (red arrow), middle lobe (blue arrow), and left upper lobe infiltrates
(green arrow).
A flexible fiberoptic bronchoscope was introduced through the endotracheal tube and advanced
to the tracheobronchial tree of both lungs under adequate sedation. Fresh blood was found throughout
the tracheobronchial tree, with no focal bleeding focus. During serial aliquoting, the blood remained
unchanged, as aliquots progressed ith 60 mL saline flushes.
A bronchoscopy image sh wed blood in the right middle lobe in the tracheobronchial tree, failing
to show the specific focal source, as shown in Figure 3.
Medicina 2019, 55, x FOR PE R REVIE  5 of 9 
 
 
Figure 2. High-resolution computed tomography (HRCT) scan showing a nodular cavity with 
infiltration in the right upper (red arrow), middle lobe (blue arrow), and left upper lobe infiltrates 
(green arrow). 
A fl xible fiberoptic bronchoscope was introduced through the endotracheal tube and advanced 
to t e tracheobronchial tree f both ungs under adequate sedation. Fresh blood was found 
t roughout the tracheobronchial tree, with no focal bleeding focus. During serial aliquoting, the 
blood remained unchanged, as aliquots progressed with 60 mL saline flushes. 
A bronchoscopy image showed blood in the right middle lobe in the tracheobronchial tree, 
failing to show the specific focal source, as shown in figure 3.  
  
A B 
Figure 3. (A) Bronchoscopy showing blood (blue arrow) in the right middle lobe in the 
tracheobronchial tree. (B) Site of blood shown in the bronchoscopy image. 
Figure 3. (A) Bronchoscopy showing blood (blue arrow) in the right middle lobe in the tracheobronchial
tree. (B) Site of blood shown in the br nc scopy image.
Medicina 2019, 55, 378 6 of 9
A microscopic evaluation of the broncho-alveolar lavage showed a red color aspirate with
numerous pulmonary alveolar macrophages and red blood cells; bacterial and fungal cultures, as well
as acid-fast staining of the broncho-alveolar aspirate were negative.
The auto-antibody panel indicated a very high level of C-ANCA. The initial laboratory tests
revealed a low estimated glomerular filtration rate and a high creatinine level, as well as an
increase in anion gap, metabolic acidosis, hyperphosphatemia, parathyroid hormone level, and a
decrease of vitamin D level. The nephrology department was consulted, and a kidney biopsy was
performed. The renal biopsy findings suggested pauci-immune (ANCA-associated), rapidly progressive
glomerulonephritis. Specifically, light microscopy revealed a medullary segment with no cortex or
glomeruli and intraluminal hyaline casts. Cortical sections contained three glomeruli containing
fibro-cellular crescents. Electron microscopy revealed wrinkled glomerular basement membranes and
capillary luminal compression with variable levels of endothelial cells and diffused effacement of the
foot processes. Additionally, scattered electron-dense mesangial deposits and a loss of brush borders
on adjacent tubules were observed. Immunofluorescence staining was inconclusive. A presumptive
diagnosis of diffuse alveolar hemorrhage due to GPA was made based on the constellation of anemia,
positive C-ANCA test, high proteinase-3 antibody titer, bronchoscopy findings of diffuse alveolar
hemorrhage without a focal source, chronic kidney disease stage-5, and renal biopsy findings of rapidly
progressive glomerulonephritis. Other differential diagnoses included:
(A) Microscopic polyangiitis—this was difficult to differentiate on the basis of the clinical background,
but a negative myeloperoxidase titer helped us to rule this out.
(B) Eosinophilic granulomatosis with polyangiitis—this was difficult to differentiate on the basis
of the clinical presentation, but this was ruled out considering the negative myeloperoxidase
findings and a normal eosinophil count.
(C) Drug-induced vasculitis—although this can have a similar presentation, a thorough history-taking
ruled out this disease.
We administered a seven-day course of plasmapheresis on alternate days together with a
combination of pulse steroids (methylprednisolone 1000 mg twice daily) for seven days and
cyclophosphamide 730 mg q3/week. Antibiotic coverage with vancomycin 1000 mg and ceftriaxone
1000 mg was also given during plasmapheresis and immunosuppressants. During treatment,
the respiratory status was supported by low tidal volume minute ventilation followed by successful
extubation. For chronic kidney disease (CKD) treatment, the patient underwent hemodialysis through
a right subclavian permanent catheter with a transition to the arteriovenous fistula route for an
outpatient dialysis route.
A multidisciplinary therapeutic approach including fluid support, ventilatory support,
plasmapheresis, pulse steroids, and cyclophosphamide led to a remarkable symptomatic improvement
of the pulmonary symptoms and to the resolution of the pulmonary imaging findings, as shown in
part B of Figure 1.
The patient was discharged with outpatient prednisone 40 mg with a taper over four weeks.
For end-stage renal disease secondary to granulomatosis with polyangiitis, our patient received
scheduled outpatient hemodialysis through an arteriovenous (AV) fistula.
3. Discussion
GPA is a chronic systemic disorder involving necrotizing inflammation of small-to-medium vessels
that may affect any organ. GPA may present with various signs and symptoms, including nonspecific
fever, arthralgia, and malaise, and may involve fatal cardiac, pulmonary, and renal manifestations [4].
GPA diagnostic criteria include the American College criterion and the Chapel Hill Consensus criterion.
According to the American College of Rheumatology criteria, a diagnosis of GPA requires two of
the following four conditions.
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1. Nasal or oral inflammation (e.g., painful or painless oral ulcers or purulent or bloody nasal
discharge).
2. Abnormal chest radiography scans showing nodules, fixed infiltrates, or cavities.
3. Abnormal urine analysis (microscopic hematuria with or without red cell casts).
4. Granulomatosis inflammation upon biopsy of an artery or perivascular area.
The Chapel Hill Consensus Criterion (CHCC) is usually not used for diagnostic purposes but
is generally used for definitions. The CHCC criteria include the size of the affected vessels and the
organ involved.
1. Large-vessel vasculitis includes Takayasu and Giant cell arteritis.
2. Medium-vessel vasculitis includes polyarteritis nodosa and Kawasaki disease.
3. Small-vessel vasculitis includes AAV, MPA, GPA, EGPA, immune complex vasculitis,
anti-glomerular basement membrane disease, cryoglobulinemic vasculitis, IgA vasculitis, and
hypocomplementemia urticarial vasculitis.
4. Variable-vessel vasculitis includes Behcet’s syndrome and Cogan’s syndrome.
5. Single-organ vasculitis includes vasculitis in only one organ with no systemic manifestation.
6. Vasculitis associated with systemic disease includes vasculitis secondary to systemic disease,
comprising rheumatoid arthritis, lupus vasculitis, etc.
7. Vasculitis associated with probable etiology, including hepatitis B, hepatitis C, and hydralazine.
The CHCC also helps exclude some AAV vasculitis with the following features:
• The absence of immune complex deposits, differentiating small vessel vasculitis from GPA, MPA,
and EGPA.
• The presence of necrotizing vasculitis without granuloma, distinguishing MPA from EGPA
and GPA.
The potential value of ANCA levels are not included as diagnostic criteria.
The lung is a common site of GPA, and DAH is a severe manifestation of this disease that affects
up to 10% of patients. DAH can present dyspnea/cough with hypoxemia, hemoptysis leading to
progressive anemia, and bronchoalveolar lavage showing blood in a diagnosed case of GPA [5,6].
The diagnosis of DAH secondary to GPA can be made by basic laboratory tests, including complete
blood count (CBC), urine analysis, serology, imaging, biopsy, and bronchoalveolar lavage findings.
The CBC can show non-specific elevations of white blood cells, platelet counts, C-reactive protein (CRP)
level, and erythrocyte sedimentation rate. Urine analysis can show RBC cast, hematuria, and even
signs of chronic kidney disease, like fatty wax cast. Serology findings include a high C-ANCA titer
with an antiproteinase-3 pattern, as seen in our patient. Chest radiography and HRCT can reveal
pulmonary nodules, ground-glass opacities, and infiltrates. Biopsy findings are a cornerstone in
the diagnosis of DAH secondary to GPA. A renal biopsy can show features consistent with GPA,
including rapidly progressive glomerulonephritis (RPGN) with or without granuloma. In the cases
of RPGN without granuloma, lung and skin biopsies can also aid in the diagnostic workup of GPA.
Skin biopsies are preferred over lung biopsy, given their less invasive nature. Bronchoalveolar lavage
(BAL) with a flexible fiberoptic bronchoscope is the gold standard test in the diagnostic workup of
DAH. In acute cases, BAL can show serial blood on three sequential aliquots without any specific
focus or, sometimes, from a single-point focus. In chronic and recurrent cases of DAH, BAL can show
hemosiderin-laden macrophages with >20% siderophages out of total pulmonary macrophages in the
specimen. This phenomenon of blood in alveoli with capillaritis in DAH can also increase the diffuse
capacity of carbon monoxide up to 30% from baseline [7,8].
Before making a diagnosis of GPA, other primary vasculitides causing DAH should be ruled out
by the absence of perinuclear-ANCA and anti-glomerular basement membrane antibodies. Infectious
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etiologies, such as hepatitis B and C viruses, human immunodeficiency virus, and pulmonary
tuberculosis, as well as secondary causes of vasculitis with similar presentations, including infectious,
drug-related, and other autoimmune diseases, must also be ruled out. As drugs such as hydralazine
and propylthiouracil can also cause ANCA vasculitis, extensive history-taking can help to rule out
drug-induced vasculitis with the differential diagnosis. In rare case, angiosarcoma of the pulmonary
vessels can also cause DAH and should be considered in differentials [8].
The pathophysiology of DAH in GPA is attributed to pulmonary vasculitis and uremia-induced
platelet dysfunction, which increases alveolar bleeding [9]. Pulmonary vasculitis can affect alveolar
capillaries and venules, likely secondary to antibody-mediated vessel destruction. Uremia-induced
platelet dysfunction increases the bleeding risk in GPA patients and can also be a potential risk of DAH.
The treatment of DAH secondary to GPA includes remission followed by maintenance therapy.
The initial management includes hemodynamically stabilization of DAH. After hemodynamic
stabilization in severe DAH, remission should be achieved with a combination of plasmapheresis
and immunosuppressants like pulse steroids and high-dose cyclophosphamide. If patients
are not responsive to steroids or cyclophosphamide, other alternative immunosuppressants,
including azathioprine, mycophenolate mofetil, etanercept, methotrexate, and rituximab, should
be administered [1,10]. The excellent efficacy of plasmapheresis was demonstrated in a retrospective
study by Klemmer et al. In this study, 20 patients received a combination of plasmapheresis with
intravenous immunosuppressive therapy and showed a 100% remission rate for pulmonary symptoms
with some improvement of renal function [3]. Another study by Frasca et al. reported that the early
administration of 3–10 plasmapheresis sessions together with immunosuppressive therapy significantly
reduced ANCA levels, which slowed the progression to end-stage renal disease and mortality [11].
In a study conducted by Cartin-Ceba et al, out of the 73 patient who had plasma exchange, 32 were not
associated with remission after 6 months (OR) of 0.49 (95% CI 0.12–1.95) p = 0.32, whereas patients
receiving Rituximab were associated with remission at 6 months (OR 6.45, 95% CI 1.78–29), p= 0.003 [12].
Thus, the therapeutic indication of plasma exchange and glucocorticoids for the treatment of AAV
remains controversial (PEXIVAS-NCT00987389). The results, so far, do not show a mortality benefit for
plasma exchange in patients with DAH [13]. Plasma exchange is also associated with an increased risk
of bleeding, and hence, citrate is used as an anticoagulant to reduce the complications [14,15].
In the present case, our patient improved after seven plasmapheresis sessions combined with
cyclophosphamide and methylprednisone. However, the patient’s renal function did not return
to normal due to the stage-5 CKD. Therefore, early diagnosis and management of GPA and DAH
showed a significant recovery of the pulmonary symptoms, with limited to no improvement of the
renal manifestation.
4. Conclusions
Physicians should include DAH as a cause of massive hemoptysis in patients with granulomatosis
with polyangiitis (GPA). DAH diagnosis relies on a combination of clinical, serologic, imaging,
and biopsy findings with bronchoalveolar lavage. The treatment of severe DAH with massive
hemoptysis can be started with multiple sessions of plasmapheresis, pulsed high-dose steroids (1 g
daily for three days and 1 mg/kg daily thereafter,) and cyclophosphamide therapy (1.2 g/pulse dose
every two weeks for the first three pulsed doses followed by infusion every third week for the next
two pulsed treatments). A combination of plasmapheresis with immunosuppressants reverses the
pulmonary symptoms and imaging findings, but a reversal of renal disease is limited.
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